Table 2.

Oral antineoplastic drugs for which absorption is changed by food

Absorption	Generic name	Molecular weight	Usage	AUC ratio	Cmax ratio	Tmax ratio	logP	lnFaSSGF	lnFaSSIF	lnFeSSIF
absorption increase	bexarotene	348.48	postprandial	8.96	7.04	–	7.46	−8.28	−4.71	−1.02
	abiraterone acetate	391.55	fasting	8.59	13.97	1.00	5.40	−6.91	−4.71	−2.16
	lapatinib tosylate hydrate	943.49	fasting	4.25	3.03	2.53	5.18	− 4.71	−5.81	−4.83
	vemurafenib	489.93	fasting	3.05	2.12	1.88	5.17	−3.82	−4.02	−2.56
	pazopanib hydrochloride	473.98	fasting	2.51	2.14	1.51	3.46	−0.77	−5.30	−2.50
	erlotinib hydrochloride	429.90	fasting	2.09	1.64	1.04	3.13	−1.70	−5.81	−2.15
	ibrutinib	440.50	not mentioned	1.86	3.15	–	2.87	−3.38	−3.65	−2.98
	nilotinib hydrochloride hydrate	584.00	fasting	1.82	2.12	1.25	5.01	−4.02	−6.21	−2.49
	ceritinib	558.14	fasting	1.54	1.45	1.33	6.08	−4.96	− 4.96	−2.15
	regorafenib hydrate	500.84	postprandial	1.48	1.73	1.5	5.30	−5.30	−4.51	−2.45
	exemestane	296.41	postprandial	1.39	1.59	1.94	3.13	−2.85	− 2.75	−2.40
	bosutinib hydrate	548.47	postprandial	1.39	1.49	1.00	4.94	1.62	−4.61	−4.51
	vorinostat	264.32	postprandial	1.38	0.91	2.67	1.59	−0.93	− 0.028	−1.37
	gefitinib	446.91	postprandial	1.37	1.32	–	4.34	0.34	−4.42	−2.75
absorption decrease	everolimus	958.24	certain conditions	0.78	0.46	2.50	5.56	−6.91	−4.96	−0.71
	trametinib dimethyl sulfoxide	693.53	fasting	0.76	0.30	2.69	2.84	−5.52	−3.30	−2.33
	dabrafenib mesylate	615.67	fasting	0.70	0.49	3.00	4.71	−4.34	−4.96	−1.08
	sorafenib tosylate	637.03	fasting	0.69	0.62	1.00	5.07	−4.96	−4.27	−2.47
	ixazomib citrate	517.13	fasting	0.68	0.30	3.92	1.53	−5.12	0.30	−0.15
	capecitabine	359.35	postprandial	0.66	0.40	2.00	1.28	−0.068	−2.28	−0.042
	afatinib maleate	718.09	fasting	0.61	0.48	2.28	4.05	0.31	−3.41	−2.03